NCT05526586已完成4 期
Twelve Week Safety, Clinical, and Microbiological Efficacy of Experimental Zinc Containing Mouth Rinses
Johnson & Johnson Consumer Inc. (J&JCI)2 个研究点 分布在 1 个国家目标入组 192 人开始时间: 2022年8月31日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 192
- 试验地点
- 2
- 主要终点
- Whole-mouth Mean Modified Gingival Index (MGI) Score After 12 Weeks of Product use
研究概览
简要总结
The purpose of this study is to evaluate the safety and efficacy of two essential oil containing experimental mouth rinse formulations and an essential oil containing mouth rinse compared to a hydroalcohol control mouth rinse for the reduction of gingivitis and plaque when used as an adjunct to tooth brushing during a twelve-week product usage period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Able to comprehend and follow the requirements and restrictions of the study (including willingness to use the assigned study products per instructions, availability on scheduled visit dates and likeliness of completing the clinical study) based upon research site personnel's assessment
- •Evidence of a personally signed and dated informed consent document indicating the subject (or legally acceptable representative) has been informed of all pertinent aspects of the trial
- •Able to read and understand the local language (participant is capable of reading the documents)
- •Adequate oral hygiene (that is, brush teeth daily and exhibit no signs of oral neglect)
- •Adults, 18 years of age and older, in good general and oral health without any known allergy to commercial dental products or cosmetics
- •Evidence of being fully vaccinated for coronavirus disease 2019 (COVID-19) (adults 60 years and older)
- •Negative pregnancy urine tests (females of child-bearing potential only)
- •Females of childbearing potential must be using a medically acceptable method of birth control for at least one month prior to Visit 1 and agree to continue using this method during their participation in the study
- •A minimum of 20 natural teeth with scorable facial and lingual surfaces. Teeth that are grossly carious, extensively restored, orthodontically banded, abutments, exhibiting severe generalized cervical and/or enamel abrasion, or third molars will not be included in the tooth count
- •A mean gingival index greater than or equal to (>=) 1.95 per the Modified Gingival Index at Baseline
- •A mean plaque index >=1.95 per the 6 site Turesky modification of the Quigley-Hein Plaque Index
- •Greater than or equal to 10 percent (%) bleeding sites at Baseline
- •Absence of significant oral soft tissue pathology, excluding plaque-induced gingivitis, based on a visual examination and at the discretion of the Investigator
- •Absence of advanced periodontitis based on a clinical examination and discretion of the dental examiner with probing depths of 4 millimeters (mm) or less except for two sites allowed with a probing depth of 5mm at Baseline
- •Absence of fixed or removable orthodontic appliance or removable partial dentures
排除标准
- •History of significant adverse effects, including sensitivities or suspected allergies, following use of oral hygiene products such as toothpastes, mouth rinses and red food dye
- •Dental prophylaxis within four weeks prior to Baseline visit
- •More than two sites that have periodontal pockets depths measuring 5mm or greater in depth
- •History of medical conditions requiring prophylactic antibiotic coverage prior to invasive dental procedures
- •Use of antibiotics, anti-inflammatory or anticoagulant therapy, phenytoin sodium or diphenylhydantoin, cyclosporin A, immunostimulants/ immunomodulators during the study or within the one month prior to the Baseline exam. Intermittent use of certain anti-inflammatory medication (ibuprofen, Aspirin); oral steroids and calcium channel blockers are acceptable at the discretion of the investigator
- •Use of chemotherapeutic anti-plaque/anti-gingivitis products such as triclosan, essential oils, cetylpyridinium chloride, sodium fluoride with CPC, stannous fluoride, zinc or chlorhexidine digluconate containing mouth rinses and toothpastes within the four weeks prior to the Baseline exam
- •Known allergy or sensitivity or history of significant adverse effects to any of the investigational product and/or product ingredients (or other ingredients in the products)
- •Consumption of probiotic drinks/supplements within one week prior to Screening/Baseline
- •Self-reported pregnancy or lactation (this criterion is due to oral tissue changes related to pregnancy and nursing which can affect interpretation of study results)
- •Self-reported smokeless tobacco user including snuff, chewing tobacco, vaping and e-cigarette usage
- •Males with a pregnant partner or a partner who is currently trying to become pregnant
- •Suspected alcohol or substance abuse (example, amphetamines, benzodiazepines, cocaine, marijuana, opiates)
- •Significant medical or oral condition which may interfere with a subject's participation in the study, including cancer, chronic kidney disease, COPD (chronic obstructive pulmonary disease), immunocompromised state (weakened immune system) from solid organ transplant, serious heart conditions, (such as heart failure, coronary artery disease, or cardiomyopathies) Sickle cell disease, Type 2 diabetes mellitus at the discretion of the Investigator
- •Participation in any clinical trial within 30 days of Screening visit
- •Diagnosed Temporo-mandibular joint dysfunction/disorder
- •Subjects who wear bruxing devices, dental aligners, retainers
- •Subjects who were previously screened and ineligible or were randomized to receive investigational product
- •Subjects who are related to those persons involved directly or indirectly with the conduct of this study (that is, principal investigator, sub-investigators, study coordinators, other site personnel, employees of Johnson & Johnson subsidiaries, contractors of Johnson & Johnson, and the families of each)
- •Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study
- •COVID-19 restrictions: Participants who fail to meet the criteria of the site's screening consent for Preventing Infection in the site's COVID-19 consent form
结局指标
主要结局
Whole-mouth Mean Modified Gingival Index (MGI) Score After 12 Weeks of Product use
时间窗: After 12 weeks
Gingivitis will be assessed by the MGI on the buccal and lingual marginal gingivae and interdental papillae of all scorable teeth: 0 (Normal \[absence of inflammation\]), 1 (Mild inflammation \[slight change in color, little change in texture\] of any portion of the entire gingival unit); 2 (Mild inflammation of the entire gingival unit); 3 (Moderate inflammation \[moderate glazing, redness, edema, and/or hypertrophy\] of the gingival unit); 4 (Severe inflammation \[marked redness and edema/hypertrophy, spontaneous bleeding, or ulceration\] of the gingival unit).
Whole-mouth Mean Plaque Index (TPI) Score After 12 Weeks of Product use
时间窗: After 12 weeks
Plaque area will be scored by the Turesky modification of the Quigley-Hein Plaque Index, on 6 surfaces (distobuccal, midbuccal and mesiobuccal, distolingual, midlingual and mesiolingual) of all scorable teeth, following disclosing: 0 (No Plaque); 1 (Separate flecks or discontinuous band of plaque around the gingival (cervical) margin); 2 (Thin (up to 1 millimeter \[mm\]), continuous band of plaque at the gingival margin); 3 (Band of plaque wider than 1mm but less than 1/3 of the surface); 4 (Plaque covering 1/3 or more, but less than 2/3 of the surface); 5 (Plaque covering 2/3 or more of the surface).
次要结局
- Whole-mouth Mean TPI Score After 1 and 4 Weeks of Product use(After Weeks 1 and 4)
- Shannon-weaver Diversity Index(At Baseline and 1, 4, and 12 weeks)
- Number of Distinct Bacterial Species(At Baseline and 1, 4, and 12 weeks)
- Categorical Species Microbial Load(At Baseline and 1, 4, and 12 weeks)
- Changes in Microbiome Composition by Sample Clustering Analysis(At Baseline and 1, 4, and 12 weeks)
- Number of Live Bacterial Counts Expressed in Log10(At Baseline and After 12 weeks)
- Whole-mouth Mean MGI Score After 1 and 4 Weeks of Product Use(After 1 and 4 weeks)
- Total Species Microbial Load(At Baseline and 1, 4, and 12 weeks)
- Whole-Mouth Mean Expanded Gingival Bleeding Index (EBI) Score at 1, 4 and 12 Weeks of Product use(Weeks 1, 4 and 12)
- Percentage of Bleeding Sites, Based on the EBI Score at 1, 4, and 12 Weeks of Product use(After 1, 4, and Week 12)
- Whole Mouth Bleeding on Probing Depth at 12 Week(At Week 12)
研究者
研究点 (2)
Loading locations...
相似试验
尚未招募
不适用
Efficacy and Safety Study of Essential Oil-Based Preparation Administered to COVID-19 PatientsCOVID-19 Respiratory InfectionCOVID-19NCT06452069Biodex S.A280
已完成
1 期
Kinetics of Etheric Oils, Smart Textiles vs. OintmentCommon ColdNCT00299559Technische Universität Dresden6
已完成
不适用
A Clinical Trial to Test the Effect of Marketed Mouth Rinses on Decreasing Plaque and Gum InflammationPlaqueGingivitisNCT02233998Johnson & Johnson Consumer and Personal Products Worldwide158
已完成
不适用
Safety of Sticker Pad Containing Essential Oil Containing Lavender and Ylang-ylang OilHealthyNCT05791266Chulalongkorn University56
已完成
不适用
Topical Phytoterpenes for Plantar FasciitisPlantar FasciitisNCT05467631Center for Biomedical Research, Inc.42